Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

Status unconfirmed · Phase 2

Conditions studied: Alzheimer's Disease

In brief

This research study will assess whether AAB-001 is safe, well tolerated and effective for use in patients with Alzheimer's Disease. AAB-001 is a new drug that is not available outside this study. AAB-001 is an antibody (a type of protein usually produced by white blood cells to destroy other substances in the body). In Alzheimer's disease a protein called amyloid gathers in the brain and is thought to cause symptoms like memory loss and confusion. It is hoped that AAB-001 will attach to the amyloid protein in your brain and help your body to remove it.

Key facts

Study ID
NCT00174525
Run by
Pharmacology Research Institute
Starts
2005-04-01
Expected to finish
2008-04-01
Last updated by the study team
2012-05-09

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.